tiprankstipranks
Trending News
More News >
Doximity (DOCS)
NYSE:DOCS
US Market
Advertisement

Doximity (DOCS) Earnings Dates, Call Summary & Reports

Compare
917 Followers

Earnings Data

Report Date
Feb 05, 2026
After Close (Confirmed)
Period Ending
2026 (Q3)
Consensus EPS Forecast
0.45
Last Year’s EPS
0.45
Same Quarter Last Year
Moderate Buy
Based on 15 Analysts Ratings

Earnings Call Summary

Q2 2026
Earnings Call Date:Nov 06, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
Doximity's earnings call highlighted strong financial performance and growth, particularly in revenue and AI adoption. Despite some uncertainties regarding future budgets and increased investment costs, the company's successful integration of Pathway and continued client engagement and expansion indicate a robust position in the market.
Company Guidance
During Doximity's fiscal 2026 second quarter earnings call, the company reported $169 million in revenue, reflecting a 23% year-over-year increase and surpassing the high end of their guidance by 7%. The adjusted EBITDA margin was 60%, amounting to $101 million, which was 15% above their guidance. The company highlighted a 32% year-over-year growth in adjusted EBITDA and a 37% increase in free cash flow. Doximity's network growth reached new heights, with over 650,000 unique prescribers using their workflow tools, and more than 50% growth in AI tool usage from the previous quarter. For the upcoming fiscal third quarter, Doximity expects revenue between $180 million and $181 million, representing 7% growth at the midpoint, and adjusted EBITDA between $103 million and $104 million, with a 57% margin. For the full fiscal year, projected revenue is set between $640 million and $646 million, with a 13% growth at the midpoint and an adjusted EBITDA margin of 55%. The company's increased outlook is largely attributed to the success of their pharma business during upsell season, driven by client portal engagement and integrated program adoption.
Record Revenue and Growth
Doximity delivered $169 million in revenue for the second quarter of fiscal 2026, representing a 23% year-on-year growth and a 7% beat from the high end of their guidance range.
Strong Financial Performance
Adjusted EBITDA margin was 60% or $101 million, 15% above the high end of guidance and grew 32% year-on-year. Free cash flow increased by 37% year-on-year.
AI and Workflow Tool Adoption
AI tools saw quarterly active prescribers up more than 50% from the prior quarter. The new AI scribe saw its number of quarterly active users nearly triple versus Q1.
Successful Pathway Acquisition Integration
Pathway's entire medical data set and AI models were fully integrated into DoxGPT just 7 weeks after acquisition, enhancing AI capabilities.
Client Engagement and Expansion
Net revenue retention rate of 118% and 121 customers contributing at least $500,000 each, up 16% from the previous year. Bookings growth in SMB customers was up roughly 100% year-over-year in Q2.

Doximity (DOCS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

DOCS Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Feb 05, 2026
2026 (Q3)
0.45 / -
0.45
Nov 06, 2025
2026 (Q2)
0.38 / 0.45
0.350.00% (+0.15)
Aug 07, 2025
2026 (Q1)
0.30 / 0.36
0.2828.57% (+0.08)
May 15, 2025
2025 (Q4)
0.27 / 0.38
0.2552.00% (+0.13)
Feb 06, 2025
2025 (Q3)
0.34 / 0.45
0.2955.17% (+0.16)
Nov 07, 2024
2025 (Q2)
0.26 / 0.30
0.2236.36% (+0.08)
Aug 08, 2024
2025 (Q1)
0.22 / 0.28
0.1947.37% (+0.09)
May 16, 2024
2024 (Q4)
0.20 / 0.25
0.225.00% (+0.05)
Feb 08, 2024
2024 (Q3)
0.24 / 0.29
0.2231.82% (+0.07)
Nov 09, 2023
2024 (Q2)
0.17 / 0.22
0.1729.41% (+0.05)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

DOCS Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 06, 2025
$62.58$54.29-13.25%
Aug 07, 2025
$58.55$66.58+13.71%
May 15, 2025
$58.45$52.56-10.08%
Feb 06, 2025
$58.26$79.23+35.99%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Doximity (DOCS) report earnings?
Doximity (DOCS) is schdueled to report earning on Feb 05, 2026, After Close (Confirmed).
    What is Doximity (DOCS) earnings time?
    Doximity (DOCS) earnings time is at Feb 05, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is DOCS EPS forecast?
          DOCS EPS forecast for the fiscal quarter 2026 (Q3) is 0.45.

            Doximity (DOCS) Earnings News

            DOCS Earnings: Doximity Stock Gains on Impressive Q4 Report
            Premium
            Market News
            DOCS Earnings: Doximity Stock Gains on Impressive Q4 Report
            2y ago
            Doximity (NYSE:DOCS) Surges after Q2 Results Beat Estimates
            Premium
            Market News
            Doximity (NYSE:DOCS) Surges after Q2 Results Beat Estimates
            2y ago
            Doximity (NYSE: DOCS) Crashes after Lowered Guidance
            Premium
            Market News
            Doximity (NYSE: DOCS) Crashes after Lowered Guidance
            2y ago
            Doximity Dives despite Winning Earnings Report
            Premium
            Market News
            Doximity Dives despite Winning Earnings Report
            3y ago
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis